Clinical practice guideline for cognitive impairment of cerebral small vessel disease

Peng, Dantao

doi:10.1002/agm2.12073

Cited by 55 publications

(60 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CSVD is common in the population, especially in the elderly, and is implicated in up to a quarter of all strokes (Suzuyama and Yakushiji, 2020). Additionally, CSVD is widely regarded as a common cause of cognitive decline and dementia (Peng, 2019).…”

Section: Introductionmentioning

confidence: 99%

New Insights in Addressing Cerebral Small Vessel Disease: Association With the Deep Medullary Veins

Wang

et al. 2020

Front. Aging Neurosci.

View full text Add to dashboard Cite

ObjectiveTo assess the suitability of deep medullary vein visibility in susceptibility weighted imaging—magnetic resonance imaging studies as a method for the diagnosis and evaluation of cerebral small vessel disease progression.MethodsA total of 92 patients with CSVD were enrolled and baseline clinical and imaging data were reviewed retrospectively. Neuroimaging biomarkers of CSVD including high-grade white matter hyperintensity (HWMH), cerebral microbleed (CMB), enlarged perivascular space (PVS), and lacunar infarct (LI) were identified and CSVD burden was calculated. Cases were grouped accordingly as mild, moderate, or severe. The DMV was divided into six segments according to the regional anatomy. The total DMV score (0–18) was calculated as the sum of the six individual segmental scores, which ranged from 0 to 3, for a semi-quantitative assessment of the DMV based on segmental continuity and visibility.ResultsThe DMV score was independently associated with the presence of HWMH, PVS, and LI (P < 0.05), but not with presence and absence of CMB (P > 0.05). Correlation between the DMV score and the CSVD burden was significant (P < 0.05) [OR 95% C.I., 1.227 (1.096–1.388)].ConclusionThe DMV score was associated with the presence and severity of CSVD.

show abstract

Section: Introductionmentioning

confidence: 99%

New Insights in Addressing Cerebral Small Vessel Disease: Association With the Deep Medullary Veins

Wang

et al. 2020

Front. Aging Neurosci.

View full text Add to dashboard Cite

show abstract

“…At present, according to the guidelines related to VCI, CSVD is diagnosed by aetiology or classification. 32 Therefore, according to current clinical practice guidelines for cognitive impairment of CSVD in China (2019), 2 the diagnosis of cognitive impairment of CSVD must be met: (i) the establishment of the presence of cognitive impairment and (ii) the determination that CSVD is the dominant pathology that accounts for the cognitive deficits. The specific diagnostic criteria for cognitive impairment due to CSVD are listed in table 1 .…”

Section: Method/designmentioning

confidence: 99%

“… 1 More importantly, with the accelerated ageing of the population and increased incidence of CSVD, cognitive impairment of CSVD is one of the most common cognitive disorders. 2 Approximately 30%–64% of patients with CSVD have different degrees of cognitive impairment. 3 CSVD-induced vascular cognitive impairment (VCI) is the second leading cause of dementia after Alzheimer’s disease.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of eight-style Tai chi on cognitive function in patients with cognitive impairment of cerebral small vessel disease: study protocol for a randomised controlled trial

et al. 2021

View full text Add to dashboard Cite

IntroductionCerebral small vessel disease (CSVD) is a critical factor that causes cognitive decline and progresses to vascular dementia and acute cerebrovascular events. Tai chi has been proven to improve nerve plasticity formation and directly improve cognitive function compared with other sports therapy, which has shown its unique advantages. However, more medical evidence needs to be collected in order to verify that Tai chi exercises can improve cognitive impairment due to CSVD. The main purposes of this study are to investigate the effect of Tai chi exercise on neuropsychological outcomes of patients with cognitive impairment related to CSVD and to explore its mechanism of action with neuroimaging, including functional MRI (fMRI) and event-related potential (P300).Methods and analysisThe design of this study is a randomised controlled trial with two parallel groups in a 1:1 allocation ratio with allocation concealment and assessor blinding. A total of 106 participants will be enrolled and randomised to the 24-week Tai chi exercise intervention group and 24-week health education control group. Global cognitive function and the specific domains of cognition (memory, processing speed, executive function, attention and verbal learning and memory) will be assessed at baseline and 12 and 24 weeks after randomisation. At the same time, fMRI and P300 will be measured the structure and function of brain regions related to cognitive function at baseline and 24 weeks after randomisation. Recruitment is currently ongoing (recruitment began on 9 November 2020). The approximate completion date for recruitment is in April 2021, and we anticipate to complete the study by December 2021.Ethics and disseminationEthics approval was given by the Medical Ethics Committee of the Affiliated People’s Hospital of Fujian University of Traditional Chinese Medicine (approval number: 2019-058-04). The findings will be disseminated through peer-reviewed publications and at scientific conferences.Trial registration numberChiCTR2000033176; Pre-results.

show abstract

“…Up till now, there is still no globally recognized diagnostic criteria for CSVD-VCI, and therefore, our review will include patients diagnosed with CSVD-VCI according to diagnostic criteria in the international randomized controlled trials[ 59 60 61 62 ] or Clinical Practice Guideline for Cognitive Impairment of Cerebral Small Vessel Disease proclaimed by Geriatric Neurology Group, Chinese Society of Geriatrics in 2019. [63] Briefly speaking, these diagnostic criteria contain 3 key points: subjective cognitive decline and objective evidence of cognitive impairment, neuroimaging evidence of CSVD, and identification of CSVD as evidence of cognitive impairment (namely, exclusion of cognitive impairment caused by other diseases). In particular, included studies should pay attention to the cognitive change of patients through detecting their cognitive function before and after treatments, and use at least 1 globally standardized and validated clinical scale to quantify this change, as one of the outcomes.…”

Section: Methodsmentioning

confidence: 99%

Chinese herbal medicine for vascular cognitive impairment in cerebral small vessel disease

Zhang¹,

Liu²,

Xia

et al. 2020

Medicine

View full text Add to dashboard Cite

Background: Cerebral small vessel disease (CSVD) is the most common etiology of vascular cognitive impairment (VCI). VCI in CSVD (CSVD-VCI) shows a progressive course with multiple stages and is also associated with dysfunctions such as gait, emotional and behavioral, and urinary disturbances, which seriously affect the life quality of elderly people. In mainland China, Chinese herbal medicine (CHM) is clinically used for CSVD-VCI and presenting positive efficacy, but the evidence revealed in relevant clinical trials has not been systematically evaluated. The purpose of this study is to assess the current evidence available for the clinical efficacy and safety of CHM for CSVD-VCI. Methods: A literature search of published RCTs up to April 30, 2020, has been conducted in the following 7 electronic databases: PubMed, Embase, the Cochrane Library, Chinese National Knowledge Infrastructure Database (CNKI), Chinese Science and Technology Journals Database (VIP), Wanfang Database, and Chinese Biomedical Literature Service System (SinoMed). For unpublished studies, 2 clinical trial online registration websites will be searched: ClinicalTrials.gov and Chinese Clinical Trial Registry (ChiCTR). Only randomized controlled trials (RCTs) using CHM in the treatment of patients with CSVD-VCI, which compares CHM with no treatment, placebo, or other conventional treatments, will be included in this systematic review. Primary outcomes will be set as acknowledged scales measuring cognitive function. Secondary outcomes will involve activities of daily living, behavioral, and psychological symptoms, global performance of dementia, neurological function, biological markers of endothelial dysfunction, the clinical effective rate, and adverse events. After screening studies and extracting data, the Cochrane Collaborations tool for assessing risk of bias will be applied to assess the methodological quality of included RCTs. Review Manager Version 5.3 software will be used for data synthesis and statistical analysis. Subgroup analyses, sensitivity analyses, and meta-regression will be conducted to detect potential sources of heterogeneity. The funnel plot and Eggers test will be developed to evaluate publication bias, if available. We will perform the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to appraise the quality of evidence. Results: Evidence exhibited in this systematic review will provide practical references in the field of CHM treating CSVD-VCI. Moreover, our detailed appraisals of methodological deficiencies of relevant RCTs will offer helpful advice for researchers who are designing trials of CHMs in the treatment of CSVD-VCI. Conclusion: The conclusion about the clinical efficacy and safety of CHM for CSVD-VCI will be provided for clinical plans, decisions, and policy developments in the full version of this systematic review. Systematic review registr...

show abstract

Clinical practice guideline for cognitive impairment of cerebral small vessel disease

Cited by 55 publications

References 60 publications

New Insights in Addressing Cerebral Small Vessel Disease: Association With the Deep Medullary Veins

New Insights in Addressing Cerebral Small Vessel Disease: Association With the Deep Medullary Veins

Evaluation of eight-style Tai chi on cognitive function in patients with cognitive impairment of cerebral small vessel disease: study protocol for a randomised controlled trial

Chinese herbal medicine for vascular cognitive impairment in cerebral small vessel disease

Contact Info

Product

Resources

About